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ABSTRACT
Objective: Hyperglycemia and hyperlipidemia in diabetes mellitus (DM) can lead an atherosclerosis. The increase of low-density lipoprotein 
level in DM and atherosclerosis is correlated with lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces 
lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids. LysoPC regulated inflammation mediators, include cytokines, adhesion 
molecules (such as vascular cell adhesion molecule-1 [VCAM-1] and intercellular adhesion molecules-1 [ICAM-1]), and monocyte chemoattractant 
protein-1 (MCP-1) chemotactic. Darapladib is known as a Lp-PLA2 specific inhibitor. It is also considered to be an atherosclerosis treatment. The aim 
of this study is to know darapladib effect on VCAM-1 and ICAM-1 aorta expression in early stages of atherosclerosis using Sprague-Dawley Type 2 DM 
(T2DM) model.
Methods: About 30 Spraque-Dawley rats are divided into three main groups: Normal, T2DM, and T2DM with darapladib administration group. Each 
group consists of 2 serials treatment time: 8 and 16 weeks treatment group. Fasting blood glucose, resistance insulin, and lipid profile were measured 
and analyzed to ensure T2DM model. VCAM-1 and ICAM-1 expression were measured using double staining immunofluorescence. Each data were 
analyzed using one-way ANOVA.
Results: There is a significant difference in VCAM-1 expression in T2DM group (8 and 16 weeks), with p=0.011 and 0.034 (p<0.05), respectively. 
Mean while, a significant difference for ICAM-1 only showed in 8 weeks T2DM group with p=0.03 (p<0.05). Moreover, there is a decreasing trend in 
16 weeks T2DM group.
Conclusion: Our results showed that darapladib can decrease VCAM-1 and ICAM-1 aorta expression in early stages of atherosclerosis using Sprague-
Dawley T2DM model. This showed another evidence of darapladib as atherosclerosis treatment.
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INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic diseases characterized 
by hyperglycemia as a result of a decrease in insulin, insulin action, or 
of both [1]. International Diabetes Federation (2013) state that there 
are about 382 million adults or about 8.3% who had diabetes, and this 
number is expected to increase until 592 million in <25 years [2]. The 
high prevalence of diabetes is expected to increase atherosclerosis 
prevalence [3]. This is because DM is a major risk factor for 
atherosclerosis development and clinical manifestations, including 
coronary artery disease, stroke, and peripheral vascular disease [4].
Hyperglycemia induces most of the changes at the cellular level in vascular 
tissue that potentially accelerate atherosclerosis process [5]. Atherosclerosis 
is influenced by cellular adhesion molecules (CAM) interaction [6]. High 
low-density lipoprotein (LDL) level in atherosclerosis can increase free 
radical that vulnerable to various oxidative process and triggered pro-
inflammatory cells recruitment and adherence [7]. Atherosclerosis affects 
a discrete portion of the blood vessels, such as vessel curvature and 
bifurcation. These sections are marked by disturbed oscillatory flow which 
induces the upregulation of adhesion molecules pro-inflammatory, such 
as inter CAM (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1. 
Chemokines will stimulate leukocytes and upregulate α4 and β2 integrin 
binding to VCAM-1 and ICAM-1, which will mediate the next stage [8].
LDL, oxidized LDL (oxLDL), and free fatty acid level were increased 
in T2DM (T2DM) [9]. LDL cholesterol is harmful because of lipid 
peroxidation process (auto-oxidation) [7]. LDL is closely related 
with enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2). 
This enzyme was originally known as platelet-activating factor-
acetylhydrolase (PAF-AH), which had two biological activities such 
as inactivate PAF-AH pro-inflammatory mediators and hydrolyze 
oxidative modified polyunsaturated fatty acids that produce 
lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty 
acids (OxNEFA). OxNEFA have chemotactic activity of monocytes, and 
LysoPC is regulating inflammatory mediators, including cytokines, 
adhesion molecules, and MCP-1 chemotactic mediator [10].
Darapladib was known as a specific inhibitor of Lp-PLA2 and already 
developed as a drug for atherosclerosis [11]. Until now a Lp-PLA2 role in 
atherogenesis still ambiguous [12]. There are few studies of darapladib 
effects in atherosclerosis. One of them is the research conducted by 
Heriansyah et al. It showed that darapladib administration can reduce 
ox-LDL and foam cell amount [4].
Therefore, the aim of this study is to know darapladib effect on VCAM-1 
and ICAM-1 aorta expression in early stages of atherosclerosis using 
Sprague-Dawley T2DM model. In this way, the result of this research can 
be useful for darapladib evidence as atherosclerosis drug because it is 
still controversial whether darapladib has a positive or negative effect.
METHODS
Study groups
This study used 4 weeks male Sprague-Dawley and weight around 
150-200 g. Samples were obtained from Bogor Agricultural University, 
Bogor, Indonesia. These rats were divided into three main groups: 
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Normal, T2DM, and T2DM with darapladib administration group. Each 
group consists of 2 serials treatment time: 8 and 16 weeks. T2DM 
model groups (T2DM) which fed with high-fat diet and injected with 
streptozotocin (STZ) intraperitoneal low dose 35 mg/kgBW. Darapladib 
was obtained from GlaxosmithKline. Samples were given darapladib 
orally 20 mg/kgBW once a day according to the time serial groups 
given. Normal rats food contained 3.43 kcal/g total energy calories, 
while the HFD contained 5.29 kcal/g total calorie energy. 30 g of food 
were given for each rat everyday. Parameters measurement was done 
at the Central Laboratory of Biological Sciences, Brawijaya University.
Measurement to ensure T2DM model
Blood glucose measurement
STZ 20 mg/kgBW was administered before blood glucose first 
measurement to induce T2DM. T2DM was diagnosed after blood 
glucose level measurement using GlucoDR blood glucose test meter (All 
Medicus Co., Ltd., Dongan-gu, Anyang-si, Korea). T2DM was diagnosed 
after obtaining fasting blood glucose levels >126 mg/dl in rats.
Insulin resistance measurement
Insulin in rat’s blood plasma was measured using Rat INS (insulin) 
ELISA kit (Cat. No. E-EL-R2466). The obtained results are still in 
ng/mL units. Plasma insulin levels were converted into IU/L. WHO 
formula was used by dividing the result with 0.0347, as 1 IU is 
equivalent with 0.0347 mg/L [13]. Insulin resistance can be measured 
with homeostatic model assessment-insulin resistance (HOMA-IR) 
formula especially in rats, which required some data, such as fasting 






HOMA-IR: Homeostatic model assessment-insulin resistance
FBG: Fasting blood glucose (mmol/L)
FINS: Fasting insulin plasma (microU/L).
Interpretation of HOMA-IR calculation in rats is if the result >1.716 then 
it can be categorized as insulin resistance with 83.87% sensitivity and 
80.56% specificity (95% confidence interval) [15].
Lipid profile measurement
Lipid profiles total cholesterol, high-density lipoprotein (HDL), and LDL 
were measured in rat blood serum using EnzyChrom™ kit.
VCAM-1 AND ICAM-1 EXPRESSION MEASUREMENT USING DOUBLE 
STAINING IMMUNOFLUORESCENCE
VCAM-1 and ICAM-1 in aortic tissue was measured by 
immunofluorescence. Aortic tissue was previously fixed with PHEMO 
buffer (68 mM PIPES, 25 mM, HEPES, pH 6.9, 15 mM EGTA, 3 mM MgCl2, 
10% [v/v] dimethyl sulfoxide containing 3.7% formaldehyde, and 
0.05% glutaraldehyde) and were processed by immunofluorescence 
labeling with anti-rat antibody ICAM-1 using rhodamin secondary 
antibody (BIOS Inc., Boston, MA, USA) and anti-rabbit antibody VCAM-1 
using FITC secondary antibody (Santacruz, USA). This parameter 
was observed with confocal laser scanning microscopy (Olympus 
Corporation, Tokyo, Japan) and was quantitatively analyzed using 
Olympus FluoView software (version 1.7A; Olympus Corporation).
Statistical analysis
Blood glucose, insulin resistance, lipid profile, VCAM-1, and ICAM-1 
expression were documented, and normality test was performed to 
determine the normality of data. Data were analyzed using one-way 
ANOVA and continue with Duncan multiple range test to compare each 
groups (more than two groups). All the analysis was performed using 
SPSS statistical software, version 16.0 and p<0.05 was considered to be 
statistically significant.
Animal ethical approval
Ethical approval was obtained for the animal treatment and 
experimental processes in this study from the Animal Care and Use 
Committee Brawijaya University Number 400/EC/KEPK/10/2016.
RESULTS
Fasting blood glucose, insulin resistance, and lipid profile were 
measured to ensure T2DM model in Sprague-Dawley rats. T2DM model 
was made successfully if fasting blood glucose >126 mg/dl and insulin 
resistance (using HOMA-IR) results >1.716 (Table 1). Table 1 shows 
that there is a significance different in lipid profile (cholesterol total, 
HDL, and LDL) between normal and DM group. This result shows that 
Sprague-Dawley T2DM model was successfully made.
From the conducted research, the average of VCAM-1 expression 
was ranged from 611.1402 to 999.0005 pg/ml. The lowest VCAM-1 
expression was normal 8 weeks group (611.1402 pg/ml), compared with 
the other groups (normal 16 weeks, 8 weeks DM, DM 16 weeks, Duchenne 
muscular dystrophy patients (DMDP) 8 weeks, and 16 weeks DMDP). 
For normal 16 weeks group, VCAM-1 expression (768.1375 pg/mI) was 
higher than DMDP groups (8 and 16 weeks). The highest expression of 
VCAM-1 (999.0005 AU) was DM 16 weeks group (Table 1).
There are significant differences in the expression of VCAM-1 between 
DM and DMDP group. The expression of VCAM-1 in DM 8 weeks is 
911.8187 and VCAM-1 expression in DMDP 8 weeks is 596.2806, with 
p=0.011 (p<0.05). While the expression of VCAM-1 in DM 16 weeks is 
999.0005 and the average expression of VCAM-1 on DMDP 16 weeks is 
684.7586, with p=0.034 (p<0.05).
Meanwhile, the average expression of ICAM-1 was observed from 
442.5055 to 1010,727 pg/ml. The lowest ICAM-1 expression was 
DMDP 8 weeks group (442.5055). For normal 16 weeks group, ICAM 
I expression (542.0247) is lower than DMDP groups (8 and 16 weeks). 
The highest ICAM-1 expression (1010.727) was DM 16 weeks group 
(Table 1).
This study showed a significant decrease in ICAM-1 expression between 
DM 8 weeks group and DMDP 8 weeks group with an average ICAM-1 
expression 991.274 and 573.9291, respectively, with p=0.03 (p<0.05). 
Meanwhile, there is no significant difference in DM 16 weeks and 
DMDP 16 weeks group, although showed a decreasing trend, with the 
average of ICAM-1 expression is 1010.727 and 874.8462, respectively, 
with p=0.884 (p<0.05). An example for VCAM-1 and ICAM-1 expression 
using immunofluorescence can be seen in Fig. 1.
DISCUSSION
Darapladib is a carbon-based small molecules that are taken orally 
which specifically inhibits Lp-PLA2 at certain doses. Inhibition of 
Lp-PLA2 is expected to decrease oxidation of phospholipids in the 
vascular space and will reduce adhesion molecules expression and 
Fig. 1: (a) Intercellular cell adhesion molecules-1 expression 
using rhodamin secondary antibody and (b) Vascular cell 
adhesion molecule-1 expression using FITC secondary antibody
ba
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other factors that lead to atherosclerosis. Darapladib has been shown 
to reduce the content of LysoPC and the expression of 24 genes related 
with macrophages and T lymphocytes function, with a decrease in 
plaque and necrotic areas [16].
Based on research conducted by Wang et al. in 2011 with the title 
inhibition of Lp-PLA2 ameliorates and decreases inflammation of 
atherosclerotic plaque formation in ApoE-deficient mice, showed 
expression of VCAM-1 and ICAM-1 were lower in the group 
darapladib [17]. This is consistent with the results in this study that 
showed significant differences in VCAM-1 expression between the DM 
group with DMDP.
The decreased expression of VCAM-1 in darapladib group could be 
due to the darapladib action as a Lp-PLA2 specific inhibitor. This 
action causing a decrease of LysoPC, Lp-PLA2 product, which induces 
a wide variety of inflammatory gene expression. LysoPC can stimulate 
the expression of VCAM-1/ICAM-1 and MCP-1 in endothelial cells or 
vascular smooth muscle cell [17]. With the Lp-PLA2 inhibition may 
decrease LysoPC and ultimately reduce the expression of VCAM-1.
VCAM-1 known to have an important role in atherosclerosis. This is due 
to tumor necrosis factor-α (TNF-α) signaling pathways. TNF-α has been 
known to have an important role in the initiation of inflammation [18]. 
TNF-α signaling pathways mediated by nuclear factor-kappa-B and 
responsible for adhesion molecules expression such as VCAM-1 and 
ICAM-1 in the endothelium. TNF-α is known to induce the expression 
of ICAM-1, likely through the protein kinase C (PKC)-δ. The adhesion 
molecules allow leukocytes are sticking to endothelium and their 
transmigration into peripheral tissues [19]. An increased expression of 
membrane-bound VCAM-1 can reflect atherosclerotic lesion formation 
progression [20].
In their research, Sumagin et al. examined the role of ICAM-1 and the 
possible role of leukocyte-endothelial interactions also the regulation 
of the vascular permeability. During inflammation development, there 
are two major events. Leukocytes will interact with endothelium in the 
process that will lead to the cells passing through the barrier created by the 
endothelial cells. Migration of these cells will lead to vascular permeability 
modification which causes a transfer of solutes into peripheral tissues. 
Sumagin et al. showed that both arterioles and venules can respond 
pro-inflammatory stimuli. Under basal conditions, changes in vascular 
permeability associated with the expression of ICAM-1 on PKC [21].
In this study showed a significant increase in adhesion molecule 
between normal and DM group. This may be caused by hyperglycemia 
in DM. Hyperglycemia can enhance monocyte adhesion to endothelial 
cells [22]. Meanwhile, in this study shows a decrease in ICAM-1 
expression between DM 8 weeks and DMDP 8 weeks groups with 
p=0.03 (p<0.05). While there was no significant decrease in DM 
16 weeks and DMDP 16 weeks group, although showed a decreasing 
trend (p<0.05). Decreased expression of ICAM-1 on darapladib 
administration is still controversial. Research conducted by Hu et al. in 
2011 showed that darapladib only decreased the expression of VCAM-1 
but do not decrease the expression of ICAM-1 [23]. Meanwhile, research 
conducted by Wang et al. in 2011 showed that the expression of ICAM-1 
in the darapladib group is lower than the positive control group [17], 
which is same with this study.
CONCLUSION
Our results study showed that darapladib can decrease VCAM-1 
and ICAM-1 aorta expression in early stages of atherosclerosis using 
Sprague-Dawley T2DM model. This showed another evidence of 
darapladib as atherosclerosis treatment.
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